BIOFIRE® Respiratory 2.1 (RP2.1) Panel & Respiratory 2.1 plus (RP2.1plus) Panel
1 Test. Up to 23 Targets. ~45 Minutes.
The BIOFIRE RP2.1 and RP2.1plus Panels use the syndromic approach to accurately detect and identify the pathogens most associated with respiratory infections. Fast and comprehensive results may enable better-informed diagnosis and treatment of patients.
Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.
BIOFIRE® RP2.1plus Panel is not available for sale in the USA.
- BIOFIRE R Panels
- Overview
- Panels Menu
- Services & Support
- Specs & Resources
Overview
Simple, Comprehensive Respiratory Testing
- Simple: 2 minutes hands-on time
- Fast: Turnaround time of about 45 minutes
- Comprehensive: Simultaneously tests for 22 targets, including RSV, SARS-CoV-2, and influenza
- Accurate: The average sensitivity is 97.1%, and the average specificity is 99.3%1
*Based on the prospective portion of the clinical study for the BIOFIRE® FILMARRAY® Respiratory 2 Panel
**Overall performance based on prospective SARS-CoV-2 clinical study for the BIOFIRE® Respiratory 2.1 Panel in comparison to 3 EUA tests, Data on file, BioFire Diagnostics.
Improve Clinical Outcomes
Because clinical symptoms for different respiratory illnesses are usually very similar, in vitro diagnostic molecular methods are often necessary to determine the causative agents. Early, rapid, and specific detection using nested multiplex PCR is essential to provide patient-tailored therapy for better outcomes. An accurate diagnosis may also help to control outbreaks, reduce potential antimicrobial resistance (AMR), and facilitate a more rapid patient recovery.
Studies show that the BIOFIRE Respiratory 2.1 and 2.1plus Panels can deliver excellent clinical and economic outcomes:
- Dramatically reduce time to diagnosis.2-4,6
- Improve patient management.2-6
- Reduce total cost of care and resource utilization.6
- Prevent secondary spread of infection.5,6
- Prevent exposure to unnecessary antibiotics.3-6
- Detect more positives and co-infections than non-panel assays.1
- Provide more timely and effective treatment.3-6
- Result in shorter hospital stays.4,6
- Reduce unnecessary or ancillary testing.4,5
References
1. Kitano, Taito et al. J Infect Chemother. 2020;26(1):82-85. doi:10.1016/j.jiac.2019.07.014
2. Pettit N, et al. J. Med Microbiol., March 2015 64:312-313.
3. Gelfer G, et al. Diag Micro Infect Dis. 2015;83:400-406.
4. Rappo U, et al. J. Clin. Microbiol. JCM.00549-16.
5. Subramony A, et al. J Pediatr. 2016; doi:10.1016/jpeds. 2016.02.050.
6. Rogers BB, et al. Arch Pathol Lab Med. 2015;139:636-641.
Services & Support
Customer Support: bioMérieux offers the best possible support with dedicated BIOFIRE® technical experts.
Application Specialists: bioMérieux has dedicated support teams available to help set up equipment and troubleshoot any issues.
For assistance: please contact our customer technical support team at biofiresupport@biomerieux.com
Specs & Resources
Technical Panel Specifications
Sample Handling | Performance Parameters |
---|---|
Sample Type: Nasopharyngeal Swab in transport media or saline | Hands-on time: Approx. 2 Minutes |
Sample Volume: 0.3 mL | Run Time: ~45 Minutes |
Product Name | Part Number | Quantity |
---|---|---|
BIOFIRE® RP2.1plus Panel reagent kit | 423740 | 30 Pouches |
BIOFIRE® RP2.1 Panel reagent kit | 423742 | 30 Pouches |